STOCK TITAN

Veraxa Biotech (VRXA) Stock Price, News & Analysis

VRXA NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
31 71 sessions, June 11, 2026 to September 22, 2026
Largest daily move
-55.5% close of June 16, 2026

Company Description

Veraxa Biotech (NASDAQ: VRXA) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $198.0M.

VRXA has declined 27.7% over the past month. The last closing price was $1.41.

This page collects what Stock Titan holds for VRXA, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

$1.40
-0.71%
0.01
Last updated: September 23, 2026 at 14:33
-27.7%
Performance 1 month
$198.0M

Veraxa Biotech (VRXA) closed at $1.41 on September 22, 2026. Over the past month, the price has lost 27.7%.

See what a $1,000 investment in VRXA would be worth today

VRXA Metrics & Rankings

Price returns through September 22, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

Veraxa Biotech has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include partnership, AI. View all VRXA news →

Insider Radar

Net Buyers
90-Day Summary
55,000
Shares Bought
0
Shares Sold
2
Transactions
Most Recent Transaction
Antz Christoph Rudiger (Chief Executive Officer) bought 5,000 shares @ $1.53 on August 27, 2026

Insider buying activity at Veraxa Biotech over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Revenue (latest FY)
Net Income (latest FY)
Operating Cash Flow

Upcoming Events

JAN
01
January 1, 2028 - April 30, 2028 Regulatory

VXA-102 IND/CTA readiness

Lead BiTAC-TCE VXA-102 to be IND/CTA-ready by early 2028 (2028-01-01 to 2028-04-30); milestone toward IND filing and clinic.
DEC
31
December 31, 2030 Corporate

Capital band expiry

Capital band approved at July 24, 2026 EGM expires 2030-12-31; governs company’s authorized share issuance flexibility.

Veraxa Biotech has 2 upcoming scheduled events. The next event, "VXA-102 IND/CTA readiness", is scheduled for January 1, 2028 (in 464 days). Investors can track these dates to stay informed about potential catalysts that may affect the VRXA stock price.

Short Interest History

Last 12 Months

Short interest in Veraxa Biotech (VRXA) currently stands at 203.0 thousand shares, down 46.3% from the previous reporting period, representing 0.5% of the float. Since June 2026, short interest has increased by 1894.5%. This relatively low short interest suggests limited bearish sentiment.

Days to Cover History

Last 12 Months

Days to cover for Veraxa Biotech (VRXA) currently stands at 1.0 days, down 72.5% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 3.6 days.

VRXA Company Profile & Sector Positioning

Veraxa Biotech (VRXA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Frequently Asked Questions

What is the current stock price of Veraxa Biotech (VRXA)?

The current stock price of Veraxa Biotech (VRXA) is $1.40 as of September 23, 2026.

What is the market cap of Veraxa Biotech (VRXA)?

The market cap of Veraxa Biotech (VRXA) is approximately $198.0M. Learn more about what market capitalization means .